Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFOXIRI Plus Target Therapy in Advanced Colorectal Cancer
NCT06575127Phase 2Recruiting
- Sponsor
- Al-Azhar University
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan, fluorouracil, panitumumab, cetuximab in metastatic colorectal cancer (mCRC), sponsored by Al-Azhar University. Started Aug 2024; status: recruiting.
02
Drugs
oxaliplatinirinotecanfluorouracilpanitumumabcetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06575127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575127.